Losartan
From Ganfyd
rINN: Losartan
Other Names
Cozaar®
Pharmacological Information
Pharmacology Images
Web information on Losartan
Mechanism of Action
angiotensin II receptor blocker
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Losartan (Less technical, good quality control)
Wikipedia on Losartan (Less technical, ? quality control)
Contents |
Introduction
Indications: hypertension, including patients with left ventricular hypertrophy; diabetic nephropathy in type 2 diabetes mellitus, chronic heart failure (in patients ≥ 60 years) Due to its inhibition of urate transporter 1 it is the sartan of choice in gout[1].
Administration
Oral:
usually 50 mg once daily (elderly over 75 years, moderate to severe renal impairment, intravascular volume depletion, initially 25 mg once daily); if necessary increased after several weeks to 100 mg once daily. However, there is some debate as to the benefit of increasing the dose from 50 mg to 100 mg. See the NLH Q&A Service answer Is there any evidence that increasing dose losartan from 50mg to 100mg reduces BP further? There is however some evidence that 150mg daily improves clinical outcomes in patients with heart failure compared to 50mg daily, in patients with heart failure and intolerance to ACE inhibitors. This is also consistent with work that suggests doses of losartan greater than 50mg daily has equivilent outcomes to candesartan in heart failurePMID link to reference awaited
.
Side effects
Diarrhoea, taste disturbance, cough, myalgia, asthenia, fatigue, migraine, vertigo, urticaria, pruritus, rash; rarely hepatitis, anaemia (in severe renal disease or following renal transplant), vasculitis (including Henoch-Schönlein purpura)
Interactions
Special advice
References
- ↑ Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. American journal of hypertension. 2008 Oct; 21(10):1157-62.(Link to article – subscription may be required.)
